Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Lurasidone HCl: A Phase 3 Study of Patients With Acute Schizophrenia

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Sunovion
ClinicalTrials.gov Identifier:
NCT00549718
First received: October 24, 2007
Last updated: June 5, 2014
Last verified: June 2014
Results First Received: November 8, 2010  
Study Type: Interventional
Study Design: Allocation: Randomized;   Intervention Model: Parallel Assignment;   Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor);   Primary Purpose: Treatment
Condition: Schizophrenia
Intervention: Drug: Lurasidone HCl

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
Lurasidone 40mg Lurasidone 40 mg tablets taken once a day The number of subjects in the participant flow (overall study) is based on the total number of subjects randomized (500). The number of subjects in the baseline characteristics is based on the safety population (489). All randomized subjects who received at least one dose of study medication were included in the safety analysis. This means that 3 subjects were randomized but never received a dose of study drug.
Lurasidone 80mg lurasidone 40m mg tablets taken once/day The number of subjects in the participant flow (overall study) is based on the total number of subjects randomized (500). The number of subjects in the baseline characteristics is based on the safety population (489). All randomized subjects who received at least one dose of study medication were included in the safety analysis. This means that 4 subjects were randomized but never received a dose of study drug.
Lurasidone 120mg Lurasidone 40 mg tablets taken once/day
Placebo Matching placebo to Lurasidone 40 mg taken once/day The number of subjects in the participant flow (overall study) is based on the total number of subjects randomized (500). The number of subjects in the baseline characteristics is based on the safety population (489). All randomized subjects who received at least one dose of study medication were included in the safety analysis. This means that 4 subjects were randomized but never received a dose of study drug.

Participant Flow:   Overall Study
    Lurasidone 40mg   Lurasidone 80mg   Lurasidone 120mg   Placebo
STARTED   125   123   124   128 
COMPLETED   84   86   85   73 
NOT COMPLETED   41   37   39   55 
Insufficient clinical response                20                7                18                32 
Adverse Event                6                8                7                3 
Lost to Follow-up                4                2                0                6 
Withdrawal by Subject                9                18                12                13 
Administrative                2                2                2                1 



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
Lurasidone 40mg Lurasidone 40 mg tablets taken once a day The number of subjects in the participant flow (overall study) is based on the total number of subjects randomized (500). The number of subjects in the baseline characteristics is based on the safety population (489). All randomized subjects who received at least one dose of study medication were included in the safety analysis. This means that 3 subjects were randomized but never received a dose of study drug.
Lurasidone 80mg lurasidone 40m mg tablets taken once/day The number of subjects in the participant flow (overall study) is based on the total number of subjects randomized (500). The number of subjects in the baseline characteristics is based on the safety population (489). All randomized subjects who received at least one dose of study medication were included in the safety analysis. This means that 4 subjects were randomized but never received a dose of study drug.
Lurasidone 120mg Lurasidone 40 mg tablets taken once/day
Placebo Matching placebo to Lurasidone 40 mg taken once/day The number of subjects in the participant flow (overall study) is based on the total number of subjects randomized (500). The number of subjects in the baseline characteristics is based on the safety population (489). All randomized subjects who received at least one dose of study medication were included in the safety analysis. This means that 4 subjects were randomized but never received a dose of study drug.
Total Total of all reporting groups

Baseline Measures
   Lurasidone 40mg   Lurasidone 80mg   Lurasidone 120mg   Placebo   Total 
Overall Participants Analyzed 
[Units: Participants]
 122   119   124   124   489 
Age 
[Units: Years]
Mean (Standard Deviation)
 40.7  (11.1)   38.6  (9.5)   37.7  (11.2)   38.2  (9.9)   38.8  (10.5) 
Gender 
[Units: Participants]
         
Female   40   43   32   34   149 
Male   82   76   92   90   340 
Region of Enrollment 
[Units: Participants]
         
France   0   1   1   1   3 
United States   70   64   70   67   271 
Malaysia   2   2   2   2   8 
Ukraine   13   12   12   14   51 
Romania   9   9   9   9   36 
Russian Federation   14   15   13   15   57 
India   14   16   17   16   63 


  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Change in Total PANSS Score From Baseline to the End of the Double Blind Phase   [ Time Frame: 6 weeks ]

2.  Secondary:   CGI-S From Baseline to the End of the Double-blind Treatment   [ Time Frame: 6 weeks ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.
The agreement is:
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.


Results Point of Contact:  
Name/Title: Josephine Cucchiaro
Organization: Sunovion Pharmaceuticals Inc.
phone: 201-592-2050
e-mail: josephine.cucchiaro@sunovion.com


Publications of Results:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Responsible Party: Sunovion
ClinicalTrials.gov Identifier: NCT00549718     History of Changes
Other Study ID Numbers: D1050229
2007-003819-31 ( EudraCT Number )
Study First Received: October 24, 2007
Results First Received: November 8, 2010
Last Updated: June 5, 2014